Prenatal drug exposure and neurodevelopmental programming of glucocorticoid signalling. (2nd October 2019)

• Record Type: Journal Article
• Authors: Franks, Alexis L.; Berry, Kimberly J.; DeFranco, Donald B.
• Other Names: Panzica GianCarlo guestEditor.; Melcangi Roberto C. guestEditor.
• Is Part Of: Journal of neuroendocrinology. Volume 32:Number 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-10-02
• Subjects: cannabinoid -- glucocorticoid -- hypothalamic‐pituitary‐adrenal axis -- prenatal -- stress; Neuroendocrinology -- Periodicals; 616.4
• DOI: 10.1111/jne.12786
• Languages: English
• ISSNs: 0953-8194

Abstract

Abstract: Prenatal neurodevelopment is dependent on precise functioning of multiple signalling pathways in the brain, including those mobilised by glucocorticoids (GC) and endocannabinoids (eCBs). Prenatal exposure to drugs of abuse, including opioids, alcohol, cocaine and cannabis, has been shown to not only impact GC signalling, but also alter functioning of the hypothalamic‐pituitary‐adrenal (HPA) axis. Such exposures can have long‐lasting neurobehavioural consequences, including alterations in the stress response in the offspring. Furthermore, cannabis contains cannabinoids that signal via the eCB pathway, which is linked to some components of GC signalling in the adult brain. Given that GCs are frequently used in pregnancy to prevent complications of prematurity, and also that rates of cannabis use in pregnancy are increasing, the likelihood of foetal co‐exposure to these compounds is high and may have additional implications for long‐term neurodevelopment. Here, we present a discussion of GC signalling and the HPA axis, as well as the effects of prenatal drug exposure on these pathways and the stress response, and we explore the interactions between GC and EC signalling in the developing brain and potential for neurodevelopmental consequences.